The Psychopharmacology of Aggressive Behavior: A Translational Approach Part 2 Clinical Studies Using Atypical Antipsychotics, Anticonvulsants, and Lithium
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Patients experiencing mental disorders are at an elevated risk for developing aggressive behavior. In the past 10 years, the psychopharmacological treatment of aggression has changed dramatically owing to the introduction of atypical antipsychotics on the market and the increased use of anticonvulsants and lithium in the treatment of aggressive patients.This review (second of 2 parts) uses a translational medicine approach to examine the neurobiology of aggression, discussing the major neurotransmitter systems implicated in its pathogenesis (serotonin, glutamate, norepinephrine, dopamine, and γ-aminobutyric acid) and the neuropharmacological rationale for using atypical antipsychotics, anticonvulsants, and lithium in the therapeutics of aggressive behavior. A critical review of all clinical trials using atypical antipsychotics (aripiprazole, clozapine, loxapine, olanzapine, quetiapine, risperidone, ziprasidone, and amisulpride), anticonvulsants (topiramate, valproate, lamotrigine, and gabapentin), and lithium are presented. Given the complex, multifaceted nature of aggression, a multifunctional combined therapy, targeting different receptors, seems to be the best strategy for treating aggressive behavior. This therapeutic strategy is supported by translational studies and a few human studies, even if additional randomized, double-blind, clinical trials are needed to confirm the clinical efficacy of this framework.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary analysis of functions of the temporal lobes in monkeys
KLÜVER, H. (1939) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1939.02270240017001 · Cited by 1,696
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689
Geddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.217 · Cited by 661
Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613
Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1337 · Cited by 475
Sachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A., & Bowden, C. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1146 · Cited by 424
Bowden, C. L., Grunze, H., Mullen, J., Brecher, M., Paulsson, B., Jones, M., Vågerö, M., & Svensson, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0116 · Cited by 376
Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs
SNYDER, R., TURGAY, A., AMAN, M., BINDER, C., FISMAN, S., & CARROLL, A. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00002 · Cited by 335
Donovan, S. J., Stewart, J. W., Nunes, E. V., Quitkin, F. M., Parides, M., Daniel, W., Susser, E., & Klein, D. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.818 · Cited by 273
Yatham, L. N., Grossman, F., Augustyns, I., Vieta, E., & Ravindran, A. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.2.141 · Cited by 248
Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., & Pérez, V. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1221 · Cited by 224
Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study
Nagaraj, R., Singhi, P., & Malhi, P. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210060801 · Cited by 214
Bymaster, F. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00146-7 · Cited by 200 · cited 1×
“Olanzapine Olanzapine, a thienobenzodiazepine derivative, is a bioisostere of clozapine that possesses potent antagonist properties toward 5-HT2A, D2, >1, and H1 receptors.(66,67) It also acts as a low-affinity antagonist on D1 receptors.”
BackgroundImpact of Substance Use Disorder on ADHD and Its Treatment
Wilens, T. E., & Upadhyaya, H. P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0807e20 · Cited by 188
CHANG, K., SAXENA, K., & HOWE, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000194566.86160.a3 · Cited by 182
Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation
Dickstein, D. P., Towbin, K. E., Van Der Veen, J. W., Rich, B. A., Brotman, M. A., Knopf, L., Onelio, L., Pine, D. S., & Leibenluft, E. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.044 · Cited by 148
Lithium in the Treatment of Aggression in Mentally Handicapped Patients: A Double-Blind Trial
Craft, M., Ismail, I. A., Krishnamurti, D., Mathews, J., Regan, A., Seth, R. V., & North, P. M. (1987) · British Journal of Psychiatry · doi:10.1192/bjp.150.5.685 · Cited by 114
Gobbi, G., Gaudreau, P.-O., & Leblanc, N. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000237945.35022.45 · Cited by 74 · cited 1×
“’’ It includes behaviors such as aimless wandering, pacing, cursing, screaming, biting, and fighting, and it may evolve through a verbally or physically aggressive behavior.(2) Aggression is a complex phenomenon associated with genetic, neurobiological, and psychosocial factors.”
BackgroundSelf-citationLane, S. D., Gowin, J. L., Green, C. E., Steinberg, J. L., Moeller, F. G., & Cherek, D. R. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.01.002 · Cited by 24 · cited 1×
“In a study in adults on parole or probation, aggressive responding on an in-lab measure of aggression was increased at low, short-term doses but decreased at high, short-term doses of topiramate.(145) In a comparative study using valproate, topiramate, and their”
Background
Cited by
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Self-citationGuidelines for the Pharmacotherapy of Schizophrenia in Adults
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720448 · Cited by 332
Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review
Brodie, M. J., Besag, F., Ettinger, A. B., Mula, M., Gobbi, G., Comai, S., Aldenkamp, A. P., & Steinhoff, B. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012021 · Cited by 288
Self-citationPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Self-citationEnde, G., Cackowski, S., Van Eijk, J., Sack, M., Demirakca, T., Kleindienst, N., Bohus, M., Sobanski, E., Krause-Utz, A., & Schmahl, C. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.153 · Cited by 163
Metadata
- Authors
- Comai, S., Tau, M., Pavlovic, Z., & Gobbi, G.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2012-04
- Volume
- 32
- Issue
- 2
- Pages
- 237-260
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2790941435
- Cited by
- 120
- References
- 21
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.